KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES

Summary Aim: to assess the efficacy and tolerability of Consupren (Galena, Chekia ) in some rheumatic diseases. Material and methods. Three months’ therapy by Consupren was studied in 12 patients: 4 with SLE, 4 with Behcet’s disease, 2 with rheumatoid arthritis with systemic manifestations, 2 with j...

Full description

Bibliographic Details
Main Authors: Z S Alekberova, N. S.V. Shekshina, A. V. Elonakov, V A Nassonova
Format: Article
Language:Russian
Published: IMA PRESS LLC 2001-04-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/536
_version_ 1797863040785317888
author Z S Alekberova
N. S.V. Shekshina
A. V. Elonakov
V A Nassonova
Z S Alekberova
author_facet Z S Alekberova
N. S.V. Shekshina
A. V. Elonakov
V A Nassonova
Z S Alekberova
author_sort Z S Alekberova
collection DOAJ
description Summary Aim: to assess the efficacy and tolerability of Consupren (Galena, Chekia ) in some rheumatic diseases. Material and methods. Three months’ therapy by Consupren was studied in 12 patients: 4 with SLE, 4 with Behcet’s disease, 2 with rheumatoid arthritis with systemic manifestations, 2 with juvenile rheumatoid arthritis. Sandimmune therapy was changed for Consupren in 9 patients. All patients were controlled for the level of serum creatinine and AD and had consultations with ophtalmologist. Results. 3 SLE patients treated by Consupren demonstrated decreasing of proteinuria, disease activity by SLAM and SLEDA1, the fourth patient demonstrated fading of diskoid rash and normalizing of temperature. Patients with Behcet’s disease had no episodes of ulcerous stomatitis and uveitis exacerbation, in one patient stable nodular erythema disappeared. Patients with JRA improved articular syndrome, normalized temperature, reduced acute phase indices. Both patients continue taking Consupren, RA patients had long term of onset of the disease and 111-IV radiological stage , thus the effect on the articular syndrome was not so demonstrative but the activity of the disease reduced. Conclusion: consupren is effective and well tolerable drug for patients with systemic manifestations of rheumatic diseases. No side effects were noticed.
first_indexed 2024-04-09T22:29:12Z
format Article
id doaj.art-238a5d0af4574931842e91edcaf141c5
institution Directory Open Access Journal
issn 1995-4484
1995-4492
language Russian
last_indexed 2024-04-09T22:29:12Z
publishDate 2001-04-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj.art-238a5d0af4574931842e91edcaf141c52023-03-22T13:45:37ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922001-04-01392434610.14412/1995-4484-2001-398476KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASESZ S AlekberovaN. S.V. ShekshinaA. V. ElonakovV A NassonovaZ S AlekberovaSummary Aim: to assess the efficacy and tolerability of Consupren (Galena, Chekia ) in some rheumatic diseases. Material and methods. Three months’ therapy by Consupren was studied in 12 patients: 4 with SLE, 4 with Behcet’s disease, 2 with rheumatoid arthritis with systemic manifestations, 2 with juvenile rheumatoid arthritis. Sandimmune therapy was changed for Consupren in 9 patients. All patients were controlled for the level of serum creatinine and AD and had consultations with ophtalmologist. Results. 3 SLE patients treated by Consupren demonstrated decreasing of proteinuria, disease activity by SLAM and SLEDA1, the fourth patient demonstrated fading of diskoid rash and normalizing of temperature. Patients with Behcet’s disease had no episodes of ulcerous stomatitis and uveitis exacerbation, in one patient stable nodular erythema disappeared. Patients with JRA improved articular syndrome, normalized temperature, reduced acute phase indices. Both patients continue taking Consupren, RA patients had long term of onset of the disease and 111-IV radiological stage , thus the effect on the articular syndrome was not so demonstrative but the activity of the disease reduced. Conclusion: consupren is effective and well tolerable drug for patients with systemic manifestations of rheumatic diseases. No side effects were noticed.https://rsp.mediar-press.net/rsp/article/view/536systemic lunus erythematosusjuvenile rheumatoid arthritisbehcet's diseaseconsunren
spellingShingle Z S Alekberova
N. S.V. Shekshina
A. V. Elonakov
V A Nassonova
Z S Alekberova
KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
Научно-практическая ревматология
systemic lunus erythematosus
juvenile rheumatoid arthritis
behcet's disease
consunren
title KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
title_full KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
title_fullStr KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
title_full_unstemmed KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
title_short KONSUPREN IN THETHERAPY OF RHEUMATIC DISEASES
title_sort konsupren in thetherapy of rheumatic diseases
topic systemic lunus erythematosus
juvenile rheumatoid arthritis
behcet's disease
consunren
url https://rsp.mediar-press.net/rsp/article/view/536
work_keys_str_mv AT zsalekberova konsupreninthetherapyofrheumaticdiseases
AT nsvshekshina konsupreninthetherapyofrheumaticdiseases
AT avelonakov konsupreninthetherapyofrheumaticdiseases
AT vanassonova konsupreninthetherapyofrheumaticdiseases
AT zsalekberova konsupreninthetherapyofrheumaticdiseases